We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Stocks-Factors to watch on March 15

Thu, 15th Mar 2018 05:25

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to bagging a deal to supplyHong Kong with liquefied natural gas (LNG), beating out major competitors forthe right to be the first company to supply LNG to the area. * GLENCORE: Glencore Plc, the world's biggest producer of cobalt,has agreed to sell around a third of its cobalt production over the next threeyears to Chinese battery recycler GEM Co Ltd, according to a filingby GEM on Wednesday. * BHP: BHP's Escondida copper mine in Chile, the world's largest,said on Wednesday that it has invited its powerful workers' union to start earlytalks on a new collective labor contract. * GOLD: Gold prices edged higher early Thursday and hovered near one-weekhighs hit in the previous session, as concerns over trade tensions weighed onshare markets. * OIL: Oil prices held steady on Thursday, supported by healthy globaldemand but capped by the relentless rise in U.S. production that is underminingefforts led by producer cartel OPEC to cut supplies and prop upmarkets. * EX-DIVS: Anglo American and Hammerson will trade withoutentitlement to their latest dividend pay-out on Thursday, trimming 1.37 pointsoff the FTSE 100 according to Reuters calculations. * The UK blue chip FTSE 100 index closed down 0.09 percent at7,132.69 points on Wednesday, as shares gave up early gains and finished innegative territory as points gained by Prudential and mining stocks wereoverturned by simmering fears of a global trade war that pushed Wall Street intothe red. * For more on the factors affecting European stocks, please click on: cpurl://apps.cp./cms/?pageId=livemarkets * UK CORPORATE DIARY: Phoenix Group Full Year 2017 Earnings Release OneSavings Bank Full Year 2017 Earnings Release Amryt Pharma PLC Q4 2017 Trading Statement Release Spirax-Sarco Engineering Full Year 2017 Earnings Release PV Crystalox Solar Full Year 2017 Earnings Release Old Mutual PLC Full Year 2017 Earnings Release Kier Group PLC Half Year 2018 Earnings Release Just Group PLC Full Year 2017 Earnings Release Savills Plc Full Year 2017 Earnings Release Cineworld Group plc Full Year 2017 Earnings Release TODAY'S UK PAPERS > Financial Times > Other business headlines Multimedia versions of Reuters Top News are now available for: * 3000 Xtra : visit http://topnews.session.rservices.com * For Top News : http://topnews.reuters.com (Reporting by Siju Varghese)
More News
11 Jan 2022 14:39

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

Read more
22 Nov 2021 11:37

Amryt to delist from AIM, concentrate on Nasdaq trading

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
19 Oct 2021 15:54

Amryt Pharma granted another two US patents

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.

Read more
14 Sep 2021 07:32

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Read more
6 Aug 2021 14:41

IN BRIEF: Amryt hikes guidance on record second quarter results

IN BRIEF: Amryt hikes guidance on record second quarter results

Read more
6 Aug 2021 12:02

Record second quarter sees Amryt lift guidance further

(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.

Read more
29 Jul 2021 17:10

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 11:26

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
6 Apr 2021 14:54

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Read more
31 Mar 2021 11:50

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.